Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 375 publications
Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review.
Journal: JAMA oncology
Published: August 27, 2026
Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: July 30, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.
Journal: medRxiv : the preprint server for health sciences
Published: June 05, 2026
Circulating Tumor DNA in Early Breast Cancer: A Review.
Journal: JAMA oncology
Published: May 28, 2026
Stage IV Breast Cancer Incidence and Survival, 2010-2021.
Journal: JAMA network open
Published: May 12, 2026
The role of radiation therapy in leptomeningeal disease from breast cancer - a multicenter analysis.
The role of radiation therapy in leptomeningeal disease from breast cancer - a multicenter analysis.
Journal: Clinical and translational radiation oncology
Published: May 05, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 30, 2026
Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.
Journal: JAMA network open
Published: April 09, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 20, 2026
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.
Journal: Clinical breast cancer
Published: February 19, 2026
Last Updated: 09/26/2026